Assenagon Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $164M | Buy |
1,812,926
+547,212
| +43% | +$45.8M | 0.2% | 91 |
|
|
2026
Q1 | $101M | Sell |
1,265,714
-1,020,584
| -45% | -$84.1M | 0.15% | 115 |
|
|
2025
Q4 | $195M | Buy |
2,286,298
+648,870
| +40% | +$53.3M | 0.27% | 62 |
|
|
2025
Q3 | $127M | Sell |
1,637,428
-855,806
| -34% | -$66.9M | 0.17% | 105 |
|
|
2025
Q2 | $195M | Sell |
2,493,234
-1,614,423
| -39% | -$120M | 0.29% | 70 |
|
|
2025
Q1 | $298M | Sell |
4,107,657
-136,319
| -3% | -$9.76M | 0.5% | 31 |
|
|
2024
Q4 | $314M | Buy |
4,243,976
+3,506,886
| +476% | +$245M | 0.51% | 31 |
|
|
2024
Q3 | $48.6M | Buy |
737,090
+81,470
| +12% | +$5.92M | 0.09% | 185 |
|
|
2024
Q2 | $60.6M | Sell |
655,620
-230,768
| -26% | -$20.4M | 0.13% | 120 |
|
|
2024
Q1 | $84.7M | Sell |
886,388
-322,631
| -27% | -$27.1M | 0.2% | 89 |
|
|
2023
Q4 | $92.2M | Buy |
1,209,019
+866,913
| +253% | +$60.3M | 0.24% | 76 |
|
|
2023
Q3 | $23.7M | Buy |
342,106
+71,028
| +26% | +$5.71M | 0.07% | 222 |
|
|
2023
Q2 | $25.6M | Sell |
271,078
-595,197
| -69% | -$51.7M | 0.09% | 186 |
|
|
2023
Q1 | $71.7M | Buy |
866,275
+16,266
| +2% | +$1.28M | 0.25% | 74 |
|
|
2022
Q4 | $63.4M | Buy |
850,009
+758,715
| +831% | +$58.5M | 0.23% | 97 |
|
|
2022
Q3 | $7.54M | Buy |
91,294
+65,114
| +249% | +$6.27M | 0.03% | 402 |
|
|
2022
Q2 | $2.49M | Buy |
26,180
+2,363
| +10% | +$245K | 0.01% | 750 |
|
|
2022
Q1 | $2.8M | Buy |
23,817
+813
| +4% | +$91.2K | 0.01% | 709 |
|
|
2021
Q4 | $2.98M | Buy |
23,004
+15,090
| +191% | +$1.76M | 0.01% | 683 |
|
|
2021
Q3 | $896K | Buy |
7,914
+5,810
| +276% | +$663K | ﹤0.01% | 934 |
|
|
2021
Q2 | $218K | Buy |
+2,104
| New | +$198K | ﹤0.01% | 1133 |
|
|
2020
Q4 | – | Sell |
-11,388
| Closed | -$909K | – | 1086 |
|
|
2020
Q3 | $909K | Sell |
11,388
-1,774
| -13% | -$138K | 0.01% | 840 |
|
|
2020
Q2 | $910K | Sell |
13,162
-252,356
| -95% | -$17.9M | 0.01% | 822 |
|
|
2020
Q1 | $16.7M | Buy |
265,518
+262,233
| +7,983% | +$18.9M | 0.13% | 121 |
|
|
2019
Q4 | $255K | Sell |
3,285
-26,556
| -89% | -$2.07M | ﹤0.01% | 718 |
|
|
2019
Q3 | $2.19M | Sell |
29,841
-629,010
| -95% | -$44.2M | 0.01% | 390 |
|
|
2019
Q2 | $40.6M | Buy |
+658,851
| New | +$39.8M | 0.3% | 65 |
|
|
2019
Q1 | – | Sell |
-52,221
| Closed | -$2.67M | – | 986 |
|
|
2018
Q4 | $2.67M | Sell |
52,221
-448,668
| -90% | -$22.7M | 0.03% | 367 |
|
|
2018
Q3 | $29.1M | Buy |
+500,889
| New | +$24.5M | 0.29% | 77 |
|
|
2018
Q2 | – | Sell |
-41,463
| Closed | -$1.93M | – | 496 |
|
|
2018
Q1 | $1.93M | Buy |
+41,463
| New | +$1.8M | 0.03% | 335 |
|
|
2017
Q4 | – | Sell |
-34,446
| Closed | -$1.25M | – | 699 |
|
|
2017
Q3 | $1.25M | Buy |
+34,446
| New | +$1.31M | 0.01% | 363 |
|
|
2017
Q2 | – | Sell |
-139,431
| Closed | -$4.37M | – | 254 |
|
|
2017
Q1 | $4.37M | Sell |
139,431
-265,515
| -66% | -$8.31M | 0.09% | 105 |
|
|
2016
Q4 | $12.6M | Buy |
+404,946
| New | +$13.1M | 0.24% | 93 |
|
Other funds holding EW
Assenagon Asset Management's EW Position: Q2 2026 in Review
Assenagon Asset Management increased its Edwards Lifesciences (EW) stake by 43% in Q2 2026, buying an estimated $45.8M and bringing the position to 1,812,926 shares worth $164M. The position accounts for 0.2% of the portfolio, ranked #91.
Assenagon Asset Management first reported a position in EW in Q4 2016 and has held it in 33 quarters since. The position peaked at $314M in Q4 2024. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Assenagon Asset Management held 1,812,926 shares of Edwards Lifesciences worth $164M as of Q2 2026.
- Assenagon Asset Management bought 547,212 Edwards Lifesciences shares in Q2 2026, an estimated $45.8M.
- Edwards Lifesciences made up 0.2% of Assenagon Asset Management's portfolio in Q2 2026, its #91 holding.
- Assenagon Asset Management first reported a position in Edwards Lifesciences in Q4 2016 and has held it in 33 quarters since.
- Assenagon Asset Management's Edwards Lifesciences position peaked at $314M in Q4 2024.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.